About Y-mAbs Therapeutics, Inc. - Common Stock (YMAB)
Y-Mabs Therapeutics Inc. is a biotechnology company focused on discovering and developing innovative antibody therapeutics for the treatment of cancer, particularly in pediatric populations. The company specializes in engineered monoclonal antibodies designed to target specific tumor-associated antigens, leveraging advanced technologies to enhance therapeutic efficacy and safety. Y-Mabs is dedicated to addressing unmet medical needs by advancing its product candidates through clinical trials, with the goal of improving outcomes for patients with various forms of cancer. Read More
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session.
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
BALA CYNWYD, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Stay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) to SERB Pharmaceuticals for $8.60 per share in cash is fair to Y-mAbs shareholders.
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session.
